News Dec 01, 2022

Traphaco was honored as "Top 50 Best Performing Listed Companies in Vietnam" in 2022

On December 1st, 2022 in Ho Chi Minh City, Nhip Cau Dau Tu Magazine held a ceremony to honor "TOP 50 best performing listed companies in Vietnam for a decade". Traphaco Joint Stock Company was honored to be in the Ranking of "The 50 Best Performing Listed Companies in Vietnam" (TOP 50) in 2022.

Mr. Kim Dong Hyu - Member of the Board of Directors, Executive Vice CEO (third from left) on behalf of Traphaco JSC received the Certificate

This is the largest-scale event ever with the participation of Government leaders, financial institutions, domestic and foreign experts, and leaders of leading enterprises in Vietnam.

TOP 50 Best Performing Listed Companies is a ranking of value and prestige annually conducted by Nhip Cau Dau Tu Magazine in collaboration with Thien Viet Securities Company, with the consultation of leading economic and business experts from the Harvard Business University, referenced from the world's prestigious rankings in order to search and honor effective companies on the Vietnamese stock market.

TOP 50 is deployed on the basis of measuring business results of companies for 3 consecutive years, based on 3 growth indicators: revenue, return on equity (ROE) and Earning Per Share (EPS). The measurement results aim to objectively assess the corporate governance capacity of the enterprise.

Surveying and ranking Top 50 listed companies through scientific measurement methods according to international standards with the advice of financial analysts from Thien Viet Securities Company, Vietnam Investment Group Fund Management Company (VIG), Vietnam Capital Partners Fund Management Company (VCP). Within, there were many experts from Harvard Business School (USA) and other prestigious international business organizations.

The Survey Council of the TOP 50 project always maintains 3 criterias to select companies to enter the survey round, including: (1) Listing on the Vietnamese stock market and with a market capitalization of 1,500 billion VND or more ; (2) Revenue for 3 consecutive years is from VND 250 billion or more; (3) Profit after tax for 3 consecutive years from VND 25 billion.

The year 2022 marks the strong recovery of Vietnam's economy after the pandemic. The World Bank forecasts that Vietnam's economy will lead the region with a growth rate of 7.2% with many strong motivations from production, export, public investment, etc.

After a decade of conducting this survey, the Top 50 has become a playground for the largest and most effective businesses in Vietnam in many key economic fields such as banking, manufacturing, retail, healthcare,… Traphaco and other big enterprises in this Top 50 deserve to be honored for the positive and effective contributions of billion-dollar companies and famous Vietnamese brands in the international market.

Maintaining the leading position

Statistics show that TRA stock went against the market in 2022 when by mid-November, it achieved a growth rate of approximately 9% in market price while the VN-Index fell as deeply as 37%. This is a miracle, but more important is the performance and long-term prospects of the business.

The double wave strategy of Oriental medicine - Western medicine that Traphaco embarked on vigorously implementing since 2021 has brought spectacular results. Expected by the end of 2022: Revenue reached 2,500 billion, profit before tax reached 400 billion, these targets all exceeded the plan. This strategy has driven both key segments to double-digit growth. Traphaco's traditional medicine position is maintained thanks to key products such as Hoat Huyet Duong Nao and Boganic. Traphaco's gross profit margin reached 56.5%, the highest level among pharmaceutical companies listed on the stock exchange.

Traphaco's non-traditional medicine segment is considered to have strong bounce when accompanying the business as a strategic shareholder Daewoong, the top 3 pharmaceutical corporation in Korea. Receiving modern technology transfer from Daewoong, Traphaco is supported from the selection of suppliers of input materials to research & production of drugs, so that the Company can save time and reduce costs of research fees. The products that Traphaco received from Daewoong in the first phase of technology transfer from 2021 have been deployed to the market and have had positive and positive signals. Here, the high-quality Western medicine products received from Daewoong and distributed to the market in 2023 - 2024 are the key product groups to meet the increasing demand such as Cardiovascular, Blood Pressure, Blood Fat, Diabetes, etc.

Top 50 Best Performing listed companies in Vietnam 2022

Mr. Kim Dong Hyu - Member of the Board of Directors, Executive Vice Ceo of the Company affirmed: “The major shareholders of Traphaco, including the group of Korean shareholders, always agree on the view of supporting and facilitating the development of the Company. When Traphaco ramped up the development of non-traditional medicines, where in the past customers could only buy traditional medicines, now they can make a choice on Western medicines additionally. Developing more products, more treatment solutions, people can access more, the company's activities bring many benefits to society”.